Journal of Hematology & Oncology

official impact factor 2.93
Search for
Advanced search
Journal of Hematology & Oncology
Tools
Open Access

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

Andrea Molckovsky and Lillian L Siu*

Journal of Hematology & Oncology 2008, 1:20 doi:10.1186/1756-8722-1-20

Accesses  

  • Last 30 days: 75 accesses
  • Last year: 1044 accesses
  • All time: 4396 accesses

Cited by

BioMed Central: 2 citations

Research   Open Access Highly Accessed

Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer

Diego Serrano, Anne-Marie Bleau, Ignacio Fernandez-Garcia, Tamara Fernandez-Marcelo, Pilar Iniesta, Carlos Ortiz-de-Solorzano, Alfonso Calvo Molecular Cancer 2011, 10:96 (9 August 2011)

Abstract | Full text | PDF | PubMed

Research article   Open Access Highly Accessed

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Sean P Dineen, Laura A Sullivan, Adam W Beck, Andrew F Miller, Juliet G Carbon, Roni Mamluk, Henry Wong, Rolf A Brekken BMC Cancer 2008, 8:352 (27 November 2008)

Abstract | Full text | PDF | PubMed | Editor’s summary

CT-322, a vascular endothelial growth factor receptor 2 inhibitor based on a human fibronectin domain, shows potential in preventing tumor growth and metastasis in mouse models of pancreatic cancer, suggesting further investigation of this treatment is needed.

Google Scholar: View citations

PubMed Central: View citations